ArticleDigestive diseases and sciences2026
Prevalence and Predictors of Persistent Celiac Disease Antibody Positivity During Follow-Up.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFollow-up of patients with celiac disease includes assessment of symptoms and adherence to the gluten-free diet. Though the latter is assessed via dietitian interview, serologies are often measured as a marker of gluten avoidance. We aimed to identify demographic and clinical factors associated with continued seropositivity at least one year after diagnosis of celiac disease.
methodsWe conducted a retrospective cohort study of adult patients (≥ 18 years) seen at a celiac disease referral center during a 24-month period. We used univariate and multivariate analysis to identify which characteristics are associated with seropositivity at the time of follow-up.
resultsOf 541 patients, 156 (28.8%) had at least one positive serology (tTG IgA, deamidated gliadin IgA, or deamidated gliadin IgG) at follow-up, with over 50% of patients having been diagnosed at least 10 years prior to their follow-up visit. Compared to patients with negative serologies at follow-up, patients with persistent positivity were more likely to have been diagnosed more recently (p < 0.001), have prior antibodies checked in the past 2 years (62% vs. 47%; p = 0.01), and have race listed as non-white or unknown (35% vs 23% p = 0.004). On multivariate analysis, duration of celiac disease at time of serologic testing (odds ratio [OR] diagnosed 10 or more years prior to serology compared to 12-23 months 0.24; 95% confidence interval [CI] 0.11-0.52) and race (OR other or unknown race compared to white 1.81; 95% CI 1.15-2.83) were associated with persistent positivity. Individuals with persistent positivity were more likely to have Marsh scores of 3a or greater at follow-up compared to those with negative antibodies on univariate and multivariate analysis.
conclusionsPersistent tTG IgA or deamidated gliadin IgA/IgG positivity one year or longer after initial diagnosis is common, occurring in > 25% of patients. Persistently elevated antibodies were associated with decreased time since initial diagnosis and race. Using clinical and demographic factors, such as time since diagnosis, may help predict persistent seropositivity, which correlates with a higher likelihood of persistent villus atrophy.
Indexed as
Identifiers
41105326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.